Back Number 2012

October 30, 2012
Science For A Better Life:
150 years of Bayer: Success through innovation and change
October 30, 2012
Third quarter of 2012:
Bayer on track for a successful 2012

- Upward trend at HealthCare and CropScience continues
- Sales advanced by 11.5 percent to EUR 9,665 million
- EBIT of EUR 838 million (minus 23.7 percent)
- EBITDA before special items improved by 2.2 percent to EUR 1,845 million
- Net income of EUR 528 million (minus 17.8 percent)
- Further progress with innovation pipeline
- Group forecast for 2012 confirmed
July 31, 2012
Strong business performance in the second quarter of 2012:
Bayer raises guidance for the full year

- Sales increased by 10.0 percent to a record EUR 10,177 million
- CropScience and HealthCare sustained strong momentum, MaterialScience improved further
- EBIT of EUR 750 million (minus 41.1 percent) impacted by special items - risk provisions established for litigations
- EBITDA before special items rose by 6.7 percent to EUR 2,172 million
- Net income of EUR 494 million (minus 33.9 percent)
April 26, 2012
1st quarter of 2012:
Encouraging start to the year for Bayer

- Sales increased by 6.8 percent to a record EUR 10,056 million
- Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million
- EBITDA before special items rose by 9.4 percent to EUR 2,442 million
- Strong start to the season at CropScience - increases at HealthCare - continuing margin pressure at MaterialScience
- Net income advanced by 53.5 percent to EUR 1,050 million
- 2012 guidance confirmed
April 23, 2012
Bayer MaterialScience
Announcement of the new Senior Country Representative and President

April 5, 2012
Bayer in Japan achieved robust growth despite challenging conditions
Feburuary 28, 2012
Financial and innovation targets for 2011 achieved
Bayer: sales and EBIT at record levels
January 18, 2012
Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer's Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation

Special Interest

Media

Share Price/Index